Heather Hampel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1225176/publications.pdf

Version: 2024-02-01

		13332	12638
214	20,394	70	137
papers	citations	h-index	g-index

224	224	224	17467
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Familial Cancer, 2023, 22, 91-97.	0.9	6
2	Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. Journal of Medical Genetics, 2022, 59, 318-327.	1.5	57
3	American Gastroenterological Association Institute and College of American Pathologists Quality Measure Development for Detection of Mismatch Repair Deficiency and Lynch Syndrome Management. Gastroenterology, 2022, 162, 360-365.	0.6	4
4	Microsatellite instability in young patients with rectal cancer: molecular findings and treatment response. British Journal of Surgery, 2022, 109, 251-255.	0.1	9
5	Prevalence and Predictors of Young-Onset Colorectal Neoplasia: Insights From a Nationally Representative Colonoscopy Registry. Gastroenterology, 2022, 162, 1136-1146.e5.	0.6	14
6	Risk assessment and genetic counseling for Lynch syndrome â€“ Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling, 2022, 31, 568-583.	0.9	7
7	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Medicine, 2022, 19, e1003897.	3.9	30
8	Impact of microsatellite status in early-onset colonic cancer. British Journal of Surgery, 2022, 109, 632-636.	0.1	7
9	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Research and Treatment, 2022, 192, 639-648.	1.1	7
10	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1077-1089.	1.1	6
11	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1068-1076.	1.1	1
12	Hereditary Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 429-447.	0.9	14
13	Utilizing Public Health Frameworks and Partnerships to Ensure Equity in DNA-Based Population Screening. Frontiers in Genetics, 2022, 13, .	1.1	2
14	Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. Cancers, 2022, 14, 2426.	1.7	3
15	Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?. Journal of Clinical Oncology, 2022, 40, 2681-2692.	0.8	18
16	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	0.6	36
17	A High Percentage of Early-age Onset Colorectal Cancer Is Potentially Preventable. Gastroenterology, 2021, 160, 1850-1852.	0.6	19
18	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecologic Oncology, 2021, 160, 161-168.	0.6	24

#	Article	IF	Citations
19	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502.	2.2	27
20	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	6.1	44
21	Albert de la Chapelle (1933â€“2020). American Journal of Human Genetics, 2021, 108, 214-216.	2.6	0
22	Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529.	2.6	5
23	Stakeholdersâ€™ views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology. European Journal of Human Genetics, 2021, 29, 1634-1644.	1.4	6
24	Many Polyps but Few Referrals: A Call to Assess and Improve Referral Rates for Colon Polyposis. Diseases of the Colon and Rectum, 2021, 64, 1035-1037.	0.7	0
25	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO Precision Oncology, 2021, 5, 779-791.	1.5	31
26	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	5.1	58
27	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	0.8	40
28	Characteristics of Early-Onset vs Late-Onset Colorectal Cancer. JAMA Surgery, 2021, 156, 865.	2.2	110
29	Advanced adenomas may be a red flag for hereditary cancer syndromes. Hereditary Cancer in Clinical Practice, 2021, 19, 8.	0.6	2
30	Early age onset colorectal cancer. Advances in Cancer Research, 2021, 151, 1-37.	1.9	15
31	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	1.1	10
32	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. JCO Precision Oncology, 2021, 5, 1588-1602.	1.5	15
33	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. Nutrients, 2021, 13, 4164.	1.7	3
34	Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer. Journal of Personalized Medicine, 2021, 11, 1284.	1.1	6
35	NCCN GuidelinesÂ® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1122-1132.	2.3	68
36	Cumulative Burden of Colorectal Cancerâ€“Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	0.6	110

#	Article	IF	Citations
37	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	0.6	90
38	Tumor Budding Detection System in Whole Slide Pathology Images. Journal of Medical Systems, 2020, 44, 38.	2.2	11
39	Implementing universal cancer screening programs can help sustain genomic medicine programs. Personalized Medicine, 2020, 17, 9-13.	0.8	1
40	MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas. Human Pathology, 2020, 96, 104-111.	1.1	17
41	Patterns of Early-Onset Colorectal Cancer Among Nigerians and African Americans. JCO Global Oncology, 2020, 6, 1647-1655.	0.8	11
42	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	2.6	124
43	Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. Cancer Research, 2020, 80, 4578-4590.	0.4	26
44	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	2.3	76
45	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. Human Genetics and Genomics Advances, 2020, 1, 100010.	1.0	3
46	Comparative Effectiveness of Two Interventions to Increase Colorectal Cancer Screening for Those at Increased Risk Based on Family History: Results of a Randomized Trial. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 3-9.	1.1	9
47	Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Familial Cancer, 2020, 19, 223-239.	0.9	39
48	Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome. Human Pathology, 2020, 103, 34-41.	1.1	14
49	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	5.8	193
50	What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?. Journal of Law and the Biosciences, 2020, 7, lsaa071.	0.8	17
51	Stakeholder Perspectives on Overcoming Barriers to Cascade Testing in Lynch Syndrome: A Qualitative Study. Cancer Prevention Research, 2020, 13, 1037-1046.	0.7	12
52	Lynch Syndrome: Management of the Colon, What Operation?. , 2020, , 149-174.		1
53	Tumor Budding Detection in H&E-Stained Images Using Deep Semantic Learning. , 2020, , .		0
54	Modified captureâ€“recapture estimates of the number of families with Lynch syndrome in Central Ohio. Familial Cancer, 2019, 18, 67-73.	0.9	7

#	Article	IF	Citations
55	A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer. Gastroenterology, 2019, 157, 280-288.	0.6	32
56	Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterology, 2019, 6, e000299.	1.1	9
57	Hereditary Colorectal Cancer Syndromes. Seminars in Oncology Nursing, 2019, 35, 58-78.	0.7	15
58	â€œHistology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndromeâ€â€”reply. Human Pathology, 2019, 89, 116-117.	1.1	0
59	Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. Journal of Medical Genetics, 2019, 56, 462-470.	1.5	61
60	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	1.1	153
61	Prevalence of Germline Mutations in Polyposis and Colorectal Cancerâ€“Associated Genes in Patients With Multiple Colorectal Polyps. Clinical Gastroenterology and Hepatology, 2019, 17, 2008-2015.e3.	2.4	43
62	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	2.3	34
63	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	9.4	377
64	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1032-1041.	2.3	191
65	A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial colectomy.. Journal of Clinical Oncology, 2019, 37, TPS1587-TPS1587.	0.8	1
66	231â€ƒLow Prevalence of Gastric and Duodenal Neoplasia in Patients With Colon Polyposis of Unknown Etiology. American Journal of Gastroenterology, 2019, 114, S136-S136.	0.2	0
67	Population Screening for Hereditary Colorectal Cancer. Surgical Oncology Clinics of North America, 2018, 27, 319-325.	0.6	15
68	Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2018, 142, 523-528.	1.2	22
69	Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. Human Pathology, 2018, 78, 125-130.	1.1	28
70	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncology, 2018, 4, 806.	3.4	136
71	Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Familial Cancer, 2018, 17, 431-434.	0.9	7
72	Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 101-109.	1.8	73

#	Article	IF	Citations
73	Cancer Risks for PMS2-Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	0.8	147
74	Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. Public Health Genomics, 2018, 21, 121-132.	0.6	20
75	Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Modern Pathology, 2018, 31, 1891-1900.	2.9	57
76	Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. Health Affairs, 2018, 37, 801-808.	2.5	114
77	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 939-949.	2.3	116
78	Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. American Journal of Human Genetics, 2018, 103, 19-29.	2.6	36
79	Screening for Pancreatic Cancer: Who to Screen and How to Follow-Up?. , 2018, , 97-108.		0
80	Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.. Journal of Clinical Oncology, 2018, 36, e18705-e18705.	0.8	0
81	Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance. Journal of Genetic Counseling, 2017, 26, 866-877.	0.9	50
82	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nature Communications, 2017, 8, 14755.	5.8	96
83	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncology, 2017, 3, 464.	3.4	510
84	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecologic Oncology, 2017, 146, 588-595.	0.6	77
85	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1465-1475.	2.3	109
86	Mutation Frequencies in Patients With Early-Onset Colorectal Cancerâ€"Reply. JAMA Oncology, 2017, 3, 1587.	3.4	5
87	Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2568-2575.	0.8	122
88	Variable DNA mismatch repair-associated gene profiles in colorectal versus uterine cancers.. Journal of Clinical Oncology, 2017, 35, 11610-11610.	0.8	0
89	Prevalence of Mutations in Adenomatous Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colon Polyps Stratified by Age. American Journal of Gastroenterology, 2017, 112, S46-S47.	0.2	0
90	Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndromeâ€"Associated Neoplasms. American Journal of Clinical Pathology, 2016, 146, 50-56.	0.4	24

#	Article	IF	Citations
91	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1010-1030.	2.3	179
92	Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Familial Cancer, 2016, 15, 253-260.	0.9	36
93	Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. Health Affairs, 2016, 35, 1367-1373.	2.5	67
94	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A stateâ€ofâ€theâ€science review. Cancer, 2016, 122, 2633-2645.	2.0	131
95	MSH6 and PMS2 Mutation Carriers Ascertained Through Multi-gene Panel Testing May Present With a Hereditary Breast and Ovarian Cancer Phenotype. Gynecologic Oncology, 2016, 143, 194.	0.6	1
96	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology, 2016, 151, 440-447.e1.	0.6	36
97	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genetics in Medicine, 2016, 18, 863-868.	1.1	30
98	Improving performance of multigene panels for genomic analysis of cancer predisposition. Genetics in Medicine, 2016, 18, 974-981.	1.1	80
99	Genetic counseling and cascade genetic testing in Lynch syndrome. Familial Cancer, 2016, 15, 423-427.	0.9	84
100	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	3.0	29
101	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	1.1	51
102	Qualitative Comparative Analysis. Journal of Mixed Methods Research, 2016, 10, 251-272.	1.8	57
103	Comprehensive population-wide detection of Lynch syndrome in Iceland.. Journal of Clinical Oncology, 2016, 34, 1542-1542.	0.8	3
104	Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.. Journal of Clinical Oncology, 2016, 34, e15148-e15148.	0.8	0
105	Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 959-968.	2.3	80
106	Alleleâ€specific imbalance mapping at human orthologs of mouse susceptibility to colon cancer (Scc) loci. International Journal of Cancer, 2015, 137, 2323-2331.	2.3	5
107	Creation of a Network to Promote Universal Screening for Lynch Syndrome: The Lynch Syndrome Screening Network. Journal of Genetic Counseling, 2015, 24, 421-427.	0.9	28
108	Use of Whole Genome Sequencing for Diagnosis and Discovery in the Cancer Genetics Clinic. EBioMedicine, 2015, 2, 74-81.	2.7	50

#	Article	IF	Citations
109	A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine, 2015, 17, 70-87.	1.1	418
110	A Modified Lynch Syndrome Screening Algorithm in Colon Cancer. American Journal of Clinical Pathology, 2015, 143, 336-343.	0.4	27
111	ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology, 2015, 110, 223-262.	0.2	1,204
112	Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology, 2015, 149, 1446-1453.	0.6	46
113	The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. Genetics in Medicine, 2015, 17, 510-511.	1.1	30
114	Preliminary validation of a consumer-oriented colorectal cancer risk assessment tool compatible with the US Surgeon Generalâ€™s My Family Health Portrait. Genetics in Medicine, 2015, 17, 753-756.	1.1	13
115	Certified Genetic Counselors. Surgical Oncology Clinics of North America, 2015, 24, 653-666.	0.6	6
116	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	0.8	603
117	Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 4301-4308.	0.8	163
118	Sarcoma: A Lynch syndrome (LS)-associated malignancy?. Journal of Clinical Oncology, 2015, 33, 1516-1516.	0.8	6
119	PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.. Journal of Clinical Oncology, 2015, 33, 3550-3550.	0.8	4
120	Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genetics in Medicine, 2014, 16, 773-782.	1.1	62
121	Prostate cancer incidence in males with Lynch syndrome. Genetics in Medicine, 2014, 16, 553-557.	1.1	88
122	Microsatellite Instability Detection by Next Generation Sequencing. Clinical Chemistry, 2014, 60, 1192-1199.	1.5	333
123	Biallelic MUTYH mutations can mimic Lynch syndrome. European Journal of Human Genetics, 2014, 22, 1334-1337.	1.4	87
124	Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations. Gastroenterology, 2014, 147, 1308-1316.e1.	0.6	328
125	NCCN Increases the Emphasis on Genetic/Familial High-Risk Assessment in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 829-831.	2.3	35
126	Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 419-419.	0.8	0

#	Article	IF	Citations
127	Universal screening for Lynch syndrome (LS) in colorectal cancer (CRC) and survival.. Journal of Clinical Oncology, 2014, 32, 415-415.	0.8	1
128	Immunodepletion Plasma Proteomics by TripleTOF 5600 and Orbitrap Elite/LTQ-Orbitrap Velos/Q Exactive Mass Spectrometers. Journal of Proteome Research, 2013, 12, 4351-4365.	1.8	43
129	BRAF V600E Mutation Analysis Simplifies the Testing Algorithm for Lynch Syndrome. American Journal of Clinical Pathology, 2013, 140, 177-183.	0.4	46
130	Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family. Stem Cell Reports, 2013, 1, 336-349.	2.3	40
131	How do we approach the goal of identifying everybody with Lynch Syndrome?. Familial Cancer, 2013, 12, 313-317.	0.9	58
132	Phosphatase and Tensin Homolog Immunohistochemical Staining and Clinical Criteria for Cowden Syndrome in Patients With Trichilemmoma or Associated Lesions. American Journal of Dermatopathology, 2013, 35, 637-640.	0.3	18
133	Mismatch Repair Protein Deficiency is Common in Sebaceous Neoplasms and Suggests the Importance of Screening for Lynch Syndrome. American Journal of Dermatopathology, 2013, 35, 191-195.	0.3	27
134	Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1538-1575.	2.3	82
135	Prostate cancer incidence in males with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 366-366.	0.8	1
136	Differences in outcome between colorectal cancer (CRC) patients (pts) with Lynch syndrome (LS) versus MLH1 hypermethylation (MLH1 HM).. Journal of Clinical Oncology, 2013, 31, 1556-1556.	0.8	0
137	Cancer risks and mutation spectrum of mismatch repair genes in African American families with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 1530-1530.	0.8	8
138	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genetics in Medicine, 2012, 14, 670-680.	1.1	40
139	Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 2012, 14, 152-162.	1.1	83
140	Characterization of the colorectal cancerâ€“associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genetics, 2012, 205, 25-33.	0.2	24
141	Identification of Lynch Syndrome Among Patients With Colorectal Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 1555.	3.8	443
142	Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs found in cancer patients. Human Mutation, 2012, 33, 1294-1301.	1.1	13
143	Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 2012, 21, 484-493.	0.9	119
144	An American founder mutation in MLH1. International Journal of Cancer, 2012, 130, 2088-2095.	2.3	12

#	Article	IF	Citations
145	Transition to the Clinical Doctorate: Attitudes of the Genetic Counseling Training Program Directors in North America. Journal of Genetic Counseling, 2012, 21, 136-149.	0.9	3
146	Evaluation of Allele-Specific Somatic Changes of Genome-Wide Association Study Susceptibility Alleles in Human Colorectal Cancers. PLoS ONE, 2012, 7, e37672.	1.1	8
147	Abstract 28: The Netrin-1 receptor UNC5C is a tumor suppressor in colorectal malignancies. , 2012, , .		0
148	Variants in the Netrin-1 Receptor UNC5C Prevent Apoptosis and Increase Risk of Familial Colorectal Cancer. Gastroenterology, 2011, 141, 2039-2046.	0.6	28
149	Compliance with recommended genetic counseling for Lynch syndrome: Room for improvement. Gynecologic Oncology, 2011, 120, S58-S59.	0.6	0
150	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. Gynecologic Oncology, 2011, 123, 532-536.	0.6	40
151	The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means?. Cancer Prevention Research, 2011, 4, 1-5.	0.7	138
152	Point: Justification for Lynch Syndrome Screening Among All Patients With Newly Diagnosed Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 597-601.	2.3	56
153	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
154	Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. International Journal of Colorectal Disease, 2010, 25, 703-712.	1.0	48
155	Clinical Relevance of Microsatellite Instability in Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 3380-3387.	0.8	273
156	Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. Journal of the National Cancer Institute, 2010, 102, 193-201.	3.0	328
157	Allele-specific expression of TGFBR1 in colon cancer patients. Carcinogenesis, 2010, 31, 1800-1804.	1.3	18
158	The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 2010, 12, 93-104.	1.1	250
159	Reply to L.H. Jensen et al and S. Jahn et al. Journal of Clinical Oncology, 2009, 27, e225-e225.	0.8	1
160	Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genetics in Medicine, 2009, 11, 812-817.	1.1	45
161	EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 2009, 11, 42-65.	1.1	431
162	Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecologic Oncology, 2009, 114, 128-134.	0.6	97

#	Article	IF	Citations
163	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 2009, 114, 486-490.	0.6	68
164	Identifying Lynch syndrome. International Journal of Cancer, 2009, 125, 1492-1493.	2.3	32
165	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. Familial Cancer, 2009, 8, 483-487.	0.9	14
166	Genetic Counseling Practice Analysis. Journal of Genetic Counseling, 2009, 18, 205-216.	0.9	26
167	Recontacting Patients Who have Tested Negative for BRCA1 and BRCA2 Mutations: How, Who and Why?. Journal of Genetic Counseling, 2009, 18, 527-529.	0.9	10
168	Genetic Testing for Hereditary Colorectal Cancer. Surgical Oncology Clinics of North America, 2009, 18, 687-703.	0.6	22
169	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. Obstetrics and Gynecology, 2009, 114, 530-536.	1.2	62
170	Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. Familial Cancer, 2008, 7, 341-345.	0.9	9
171	Genotyping panel for assessing response to cancer chemotherapy. BMC Medical Genomics, 2008, 1, 24.	0.7	24
172	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology, 2008, 135, 419-428.e1.	0.6	480
173	Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer. Science, 2008, 321, 1361-1365.	6.0	157
174	Origins and Prevalence of the American Founder Mutation of MSH2. Cancer Research, 2008, 68, 2145-2153.	0.4	34
175	Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 5783-5788.	0.8	760
176	A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. Journal of Medical Genetics, 2008, 45, 340-345.	1.5	47
177	The Frequency of Muir-Torre Syndrome Among Lynch Syndrome Families. Journal of the National Cancer Institute, 2008, 100, 277-281.	3.0	152
178	Prospective Evaluation of Mismatch Repair Protein Expression in Primary Colorectal Cancer. American Journal of Gastroenterology, 2008, 103, S169-S170.	0.2	0
179	Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2007, 67, 9603-9603.	0.4	88
180	Evidence for heritable predisposition to epigenetic silencing of MLH1. International Journal of Cancer, 2007, 120, 1684-1688.	2.3	75

#	Article	IF	Citations
181	Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2006, 66, 7810-7817.	0.4	564
182	Pathogenicity of MSH2 Missense Mutations Is Typically Associated With Impaired Repair Capability of the Mutated Protein. Gastroenterology, 2006, 131, 1408-1417.	0.6	59
183	Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Human Pathology, 2006, 37, 831-838.	1.1	49
184	Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer. Obstetrics and Gynecology, 2006, 108, 1208-1215.	1.2	56
185	Utilization of genetic counseling services by surgical oncologists: education a must. Clinical Genetics, 2006, 70, 524-525.	1.0	1
186	American founder mutation for Lynch syndrome. Cancer, 2006, 106, 448-452.	2.0	16
187	Long-range PCR facilitates the identification ofPMS2-specific mutations. Human Mutation, 2006, 27, 490-495.	1.1	90
188	Somatic Acquisition and Signaling of <EMPH TYPE="ITAL">TGFBR1</EMPH>*6A in Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 1634.	3.8	87
189	Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of Onset. Gastroenterology, 2005, 129, 415-421.	0.6	338
190	Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of. Gastroenterology, 2005, 129, 537-549.	0.6	89
191	Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). New England Journal of Medicine, 2005, 352, 1851-1860.	13.9	1,237
192	Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of Onset. Gastroenterology, 2005, 129, 415-421.	0.6	309
193	Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of MLH1. Gastroenterology, 2005, 129, 537-549.	0.6	170
194	Mismatch Repair Gene PMS2. Cancer Research, 2004, 64, 4721-4727.	0.4	149
195	A Founder Mutation of the <EMPH TYPE="ITAL">MSH2</EMPH> Gene and Hereditary Nonpolyposis Colorectal Cancer in the United States. JAMA - Journal of the American Medical Association, 2004, 291, 718.	3.8	75
196	Identification and characterization of genomic rearrangements ofMSH2 andMLH1 in Lynch syndrome (HNPCC) by novel techniques. Human Mutation, 2003, 22, 258-258.	1.1	87
197	Germline PTEN Promoter Mutations and Deletions in Cowden/Bannayan-Riley-Ruvalcaba Syndrome Result in Aberrant PTEN Protein and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway. American Journal of Human Genetics, 2003, 73, 404-411.	2.6	283
198	Gi Polyposis and Glycogenic Acanthosis of The Esophagus Associated With Pten Mutation Positive Cowden Syndrome in The Absence of Cutaneous Manifestations. American Journal of Gastroenterology, 2003, 98, 1429-1434.	0.2	75

#	Article	IF	Citations
199	The Founder Mutation MSH2*1906Gâ†'C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population. American Journal of Human Genetics, 2002, 71, 1395-1412.	2.6	118
200	A 39-bp Deletion Polymorphism in PTEN in African American Individuals. Journal of Molecular Diagnostics, 2002, 4, 114-117.	1.2	6
201	Novel germlineCDH1mutations in hereditary diffuse gastric cancer families. Human Mutation, 2002, 19, 518-525.	1.1	63
202	Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements. Cancer Research, 2002, 62, 4579-82.	0.4	22
203	Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*. American Journal of Human Genetics, 2001, 69, 704-711.	2.6	236
204	Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet, The, 2001, 358, 210-211.	6.3	210
205	Genetic Testing for Cancer Predisposition. Annual Review of Medicine, 2001, 52, 371-400.	5.0	103
206	Hereditary colorectal cancer: risk assessment and management. Clinical Genetics, 2001, 58, 89-97.	1.0	68
207	Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15044-15049.	3.3	399
208	Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation. American Journal of Pathology, 2000, 157, 1123-1128.	1.9	254
209	Coming of Age in the Community Setting. Oncology Issues, 1999, 14, 14-15.	0.0	0
210	Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.. Journal of Clinical Oncology, 1998, 16, 2417-2425.	0.8	435
211	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997, 17, 79-83.	9.4	630
212	Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet, The, 1996, 347, 1643-1645.	6.3	145
213	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 1996, 13, 126-128.	9.4	282
214	Universal tumor screening for lynch syndrome on colorectal cancer biopsies impacts surgical treatment decisions. Familial Cancer, 0, , .	0.9	1